Completed Clinical Trials & Completed Trials - Analysis/Publication Phase


 Completed Studies - Publication Complete
("BLINDed Withdrawal of Deprenyl in the DATATOP Extension")
 
(Comparison of the Agonist Pramipexole versus Levodopa on Motor Complications of Parkinson's Disease).
 
(Dyskinesias And Remacemide Effects)
 

(Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism)
 
 
(Earlier vs. Later L-DOPA in Parkinson’s Disease)
 
(PArkinson’s Dis Transdermal Clinical Trial Helping to Assess SPM-962 TDS)
 
(Parkinson Research Examination of CEP-1347 Trial)
 
(Parkinson's Rasagiline: Efficacy, Safety in the Treatment of "Off")
 
(PRamipexole In Minorities Efficacy)
 
(PSYchosis and CLOzapine in Parkinson’S Disease)
 
(Coenzyme Q10 Evaluation-2)
 
(Remacemide As Monotherapy in Parkinson’s Disease)
 
(A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group Study Comparing TV-1203/Carbidopa (TV-1203/CD) Dispersible Tablets with Levodopa/Carbidopa (LD/CD) Tablets in Advanced Parkinson's Disease (PD) Patients with Motor Fluctuations)
 
(REmacemide as Adjunct to Levodopa)
 
(RO-196327 Assessment and Dose Finding Study)
 
(Safety Efficacy of Entacapone Study Assessing Wearing Off)
 
(Study of Pharmacokinetic Interactions between Remacemide And Levodopa)
 
(Short Term Assessment of RO-196327 Tolerability – Levodopa Exposed)
 
(Short Term Assessment of RO-196327 Tolerability in Untreated Parkinsonism)
 
(Safety, Tolerability and Efficacy of Pramipexole in Untreated Parkinsonism)
 
(Rasagiline Mesylate (TVP-1012) in Early Monotherapy for Parkinson’s Disease Outpatients)
 
(Tolerability & Efficacy of SIB-1508Y Therapy)
 
 Completed Studies - Analysis/Publication Phase in process
(SPectroscopy IN Diagnosis of PD)
Diagnostic and Prognostic Biomarkers in Parkinson Disease

(A randomized, double-blind, active (pramipexole 0.5 mg tid) and placebo controlled, efficacy study of pramipexole, given 0.5 mg and 0.75 mg bid over a 12-week treatment phase in early PD patients)

(Parkinson’s Research:  The Organized GENetics Initiative)

(Parkinson’s Disease On EsTrogen Replacement in the Menopause Years)
 
(Effects of Coenzyme Q10 in Parkinson Disease)

 

July 27, 2012

The QE3 study was presented at the 16th International Congress of Parkinson's Disease and Movement Disorders Meeting in Dublin, Ireland in June 2012.  An abstract, or a short summary of study results, was presented at the meeting and a copy of the material is available at:

Link to abstract: http://www.mdsabstracts.com/abstract.asp?MeetingID=787&id=99428
 

May 27, 2011

The NINDS has stopped the QE3 Phase III study of Coenzyme Q10 for treatment of early Parkinson’s disease acting on the recommendation of the study’s Data Safety Monitoring Board (DSMB).

Link to Printable Statement:May 27, 2011 - Statement re Termination of QE3 Study 
 
Updated 7.25.12
 
 
 
Clinical Trials
What's New
More News
PSG Overview
Proposal Study Kit

PDtrials